Compare CCJ & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCJ | WAT |
|---|---|---|
| Founded | 1987 | 1958 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3B | 29.2B |
| IPO Year | 1998 | 1996 |
| Metric | CCJ | WAT |
|---|---|---|
| Price | $110.32 | $290.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 17 |
| Target Price | $123.92 | ★ $386.38 |
| AVG Volume (30 Days) | ★ 3.3M | 1.1M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | N/A | ★ 10.76 |
| Revenue | N/A | ★ $3,165,286,000.00 |
| Revenue This Year | N/A | $104.66 |
| Revenue Next Year | $13.55 | $10.53 |
| P/E Ratio | $118.32 | ★ $26.59 |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $35.00 | $275.05 |
| 52 Week High | $135.24 | $414.15 |
| Indicator | CCJ | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 29.95 |
| Support Level | $108.46 | $281.33 |
| Resistance Level | $110.16 | $308.14 |
| Average True Range (ATR) | 6.10 | 9.00 |
| MACD | -1.22 | -0.92 |
| Stochastic Oscillator | 22.86 | 15.59 |
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe and is one of those uranium producers. It has three reportable segments: Uranium, Fuel Services, and Westinghouse, deriving maximum revenue from the Westinghouse segment. The Uranium segment involves the exploration for, mining, milling, purchase, and sale of uranium concentrate, while the Fuel Services segment involves the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. Westinghouse Electric Company provides products and services to nuclear reactors, including outage and maintenance services, engineering support, instrumentation and controls equipment, plant modification, and components and parts.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.